aTYR PHARMA (ATYR) Short term Debt (2014 - 2020)

aTYR PHARMA (ATYR) has reported Short term Debt for 7 consecutive years, with $3.1 million the latest figure, recorded in Q3 2020.

• For the quarter ending Q3 2020, Short term Debt fell 60.98% year-over-year to $3.1 million; the trailing twelve-month figure through Sep 2020 stood at $3.1 million (down 60.98% YoY), and the FY2019 full-year result was $8.7 million, up 12.49% from the prior year.
• Short term Debt eased to $3.1 million in Q3 2020 per ATYR's latest filing, from $5.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $8.7 million in Q4 2019 and bottomed at $339000.0 in Q4 2016.
• Historically, Short term Debt has averaged $5.2 million across 5 years, with a median of $5.0 million in 2017.
• The sharpest annual moves came in 2016 and 2017: Short term Debt sank 89.93% in 2016, then surged 1378.47% in 2017.
• Over 5 years, Short term Debt stood at $339000.0 in 2016, then soared by 1378.47% to $5.0 million in 2017, then surged by 54.97% to $7.8 million in 2018, then climbed by 12.49% to $8.7 million in 2019, then sank by 64.97% to $3.1 million in 2020.
• According to Business Quant data, Short term Debt over the past three periods registered $3.1 million, $5.0 million, and $6.9 million for Q3 2020, Q2 2020, and Q1 2020 respectively.